DCPH - デシフィラ・ファ―マシュ―ティカルズ （Deciphera Pharmaceuticals Inc.）DCPHのニュース
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK at the 2023 American Society of Clinical Oncology Annual Meeting 2023/05/25 21:00:00 Wallstreet:Online
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023. “As we prepare to
State Board of Administration of Florida Retirement System Sells 5,080 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) 2023/05/22 09:09:52 EIN News Pharmaceuticals
… decreased its position in Deciphera Pharmaceuticals , Inc. (NASDAQ:DCPH – Get … for the current year. Deciphera Pharmaceuticals Company Profile (Get Rating) Deciphera … analysts'' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat …
State Board of Administration of Florida Retirement System Cuts Stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) 2023/05/22 08:58:41 The AM Reporter
State Board of Administration of Florida Retirement System lessened its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) by 23.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,620 shares of the company’s stock after selling 5,080 shares during […]
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE 2023/05/07 20:00:00 Kwhen Finance
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript 2023/05/07 08:58:09 Seeking Alpha
Deciphera Pharmaceuticals, Inc. (NASDAQ:NASDAQ:DCPH) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ETCompany ParticipantsJen Larson - Senior Vice President-Finance and Investor…
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE 2023/05/07 20:00:00 Kwhen Finance
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript 2023/05/07 08:58:09 Seeking Alpha
Deciphera Pharmaceuticals, Inc. (NASDAQ:NASDAQ:DCPH) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ETCompany ParticipantsJen Larson - Senior Vice President-Finance and Investor…
Stifel maintains Deciphera Pharma at Hold with a price target of $14.00 2023/05/04 19:11:37 Investing.com
https://www.investing.com/news/pro/deciphera-pharmaceuticals-receives-investment-bank-analyst-rating-update-3073306
Deciphera Pharmaceuticals GAAP EPS of -$0.60 misses by $0.01, revenue of $33.45M misses by $2.05M 2023/05/03 11:25:22 Seeking Alpha
Deciphera Pharmaceuticals press release (NASDAQ:DCPH): Q1 GAAP EPS of -$0.60 misses by $0.01.Revenue of $33.45M (+14.6% Y/Y) misses by $2.05M.
Recap: Deciphera Pharmaceuticals Q1 Earnings 2023/05/03 11:20:16 Benzinga
Deciphera Pharmaceuticals (NASDAQ: DCPH ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Deciphera Pharmaceuticals missed estimated earnings by 1.69%, reporting an … Full story available on Benzinga.com
Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshow 2023/03/29 15:49:16 Seeking Alpha
The following slide deck was published by Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade) 2023/03/25 12:00:00 Seeking Alpha
Last year, Deciphera Pharmaceuticals was almost destroyed by a trial failure. This year, it has had some good omens. Click here for our analysis of DCPH stock.
Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit 2023/03/18 09:21:53 Seeking Alpha
Deciphera reported total revenue of $36.3M for Q4 2022, an increase from $24.2M YoY. Learn why investors should consider DCPH as a promising long-term investment opportunity.